Sandbox:Hannan: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 58: Line 58:
# AML with biallelic mutations of CEBPA
# AML with biallelic mutations of CEBPA
# Provisional entity: AML with mutated RUNX1
# Provisional entity: AML with mutated RUNX1
AML with myelodysplasia-related changes
* AML with myelodysplasia-related changes
 
* Therapy-related myeloid neoplasms
Therapy-related myeloid neoplasms
* AML, NOS
 
# AML with minimal differentiation
AML, NOS
# AML without maturation
 
# AML with maturation
AML with minimal differentiation
# Acute myelomonocytic leukemia
 
# Acute monoblastic/monocytic leukemia
AML without maturation
# Pure erythroid leukemia
 
# Acute megakaryoblastic leukemia
AML with maturation
# Acute basophilic leukemia
 
# Acute panmyelosis with myelofibrosis
Acute myelomonocytic leukemia
* Myeloid sarcoma
 
* Myeloid proliferations related to Down syndrome
Acute monoblastic/monocytic leukemia
# Transient abnormal myelopoiesis (TAM)
 
# Myeloid leukemia associated with Down syndrome
Pure erythroid leukemia
 
Acute megakaryoblastic leukemia
 
Acute basophilic leukemia
 
Acute panmyelosis with myelofibrosis
 
Myeloid sarcoma
 
Myeloid proliferations related to Down syndrome
 
Transient abnormal myelopoiesis (TAM)
 
Myeloid leukemia associated with Down syndrome
|
|
|
|
|
|
|-
|-
|
|Blastic plasmacytoid dendritic cell neoplasm
|
|
|
|
|
|
|-
|-
|
|Acute leukemias of ambiguous lineage
* Acute undifferentiated leukemia
* Mixed phenotype acute leukemia (MPAL) with t(9;22)(q34.1;q11.2);BCR-ABL1
* MPAL with t(v;11q23.3);KMT2A rearranged
* MPAL, B/myeloid, NOS
* MPAL, T/myeloid, NO
|
|
|
|

Revision as of 12:33, 15 January 2019

Other myeloid neoplasm and acute leukemia
Myeloid/lymphoid neoplasms with eosinophilia and rearrangement of

PDGFRA, PDGFRB, or FGFR1, or with PCM1-JAK2

  • Myeloid/lymphoid neoplasms with PDGFRA rearrangement
  • Myeloid/lymphoid neoplasms with PDGFRB rearrangement
  • Myeloid/lymphoid neoplasms with FGFR1 rearrangement
  • Provisional entity: Myeloid/lymphoid neoplasms with PCM1-JAK
Myelodysplastic/myeloproliferative neoplasms (MDS/MPN)
  • Chronic myelomonocytic leukemia (CMML)
  • Atypical chronic myeloid leukemia (aCML), BCR-ABL1-
  • Juvenile myelomonocytic leukemia (JMML)
  • MDS/MPN with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T)
  • MDS/MPN, unclassifiable
Myelodysplastic syndromes (MDS)
  • MDS with single lineage dysplasia
  • MDS with ring sideroblasts (MDS-RS)
  • MDS-RS and single lineage dysplasia
  • MDS-RS and multilineage dysplasia
  • MDS with multilineage dysplasia
  • MDS with excess blasts
  • MDS with isolated del(5q)
  • MDS, unclassifiable
  • Provisional entity: Refractory cytopenia of childhood
  • Myeloid neoplasms with germ line predisposition
Acute myeloid leukemia (AML) and related neoplasms
  • AML with recurrent genetic abnormalities
  1. AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1
  2. AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22);CBFB-MYH11
  3. APL with PML-RARA
  4. AML with t(9;11)(p21.3;q23.3);MLLT3-KMT2A
  5. AML with t(6;9)(p23;q34.1);DEK-NUP214
  6. AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2);GATA2, MECOM
  7. AML (megakaryoblastic) with t(1;22)(p13.3;q13.3);RBM15-MKL1
  8. Provisional entity: AML with BCR-ABL1
  9. AML with mutated NPM1
  10. AML with biallelic mutations of CEBPA
  11. Provisional entity: AML with mutated RUNX1
  • AML with myelodysplasia-related changes
  • Therapy-related myeloid neoplasms
  • AML, NOS
  1. AML with minimal differentiation
  2. AML without maturation
  3. AML with maturation
  4. Acute myelomonocytic leukemia
  5. Acute monoblastic/monocytic leukemia
  6. Pure erythroid leukemia
  7. Acute megakaryoblastic leukemia
  8. Acute basophilic leukemia
  9. Acute panmyelosis with myelofibrosis
  • Myeloid sarcoma
  • Myeloid proliferations related to Down syndrome
  1. Transient abnormal myelopoiesis (TAM)
  2. Myeloid leukemia associated with Down syndrome
Blastic plasmacytoid dendritic cell neoplasm
Acute leukemias of ambiguous lineage
  • Acute undifferentiated leukemia
  • Mixed phenotype acute leukemia (MPAL) with t(9;22)(q34.1;q11.2);BCR-ABL1
  • MPAL with t(v;11q23.3);KMT2A rearranged
  • MPAL, B/myeloid, NOS
  • MPAL, T/myeloid, NO
Myeloproliferative neoplasms (MPN) Clinical manifestations Diagnosis Other Features
Symptoms Physical examination Laboratory Findings Bone Marrow Biopsy Gold Standard Others
Chronic myeloid leukemia

(CML), BCR-ABL1+

Chronic neutrophilic leukemia (CNL)
Polycythemia vera (PV)
Primary myelofibrosis (PMF)
  • prefibrotic/early stage
  • overt fibrotic stage
Essential thrombocythemia (ET)
Chronic eosinophilic leukemia, not otherwise specified (NOS)
MPN, unclassifiable
Mastocytosis